📰 Breaking News: Lessons Learnt & Insights from DSTBTD Restructuring Plan

Notices to creditors (MVL)

Novartis Europharm Limited

active Company no. 03068306 Published 08 October 2026

In short: Novartis Europharm Limited (company no. 03068306) entered members' voluntary liquidation, a solvent and planned closure, according to a Notices to creditors (MVL) notice published in The London Gazette on 08 October 2026. The office holders are Derek Neil Hyslop; Matthew Coomber, appointed 30 September 2026.

The joint liquidators announce a final distribution to creditors of several companies, with a deadline of 20 November 2026 to submit claims.

Notice details

Notice ID
5226872
Notice code
2433
Publication date
8 October 2026
Company
NOVARTIS EUROPHARM LIMITED (03068306); NOVARTIS GRIMSBY LIMITED (00170180); GYROSCOPE THERAPEUTICS LIMITED (10131257); GYROSCOPE THERAPEUTICS HOLDINGS LIMITED (13086765); ADVANCED ACCELERATOR APPLICATIONS (UK & IRELAND) LIMITED (04189193)
Registered office
1 More London Place, London, SE1 2AF
Principal trading address
2nd Floor, The Westworks Building White City Place, 195 Wood Lane, London, W12 7FQ
Type of liquidation
Members' Voluntary Liquidation (final distribution)
Date of appointment
30 September 2026
Office holder(s)/Liquidator(s)
Derek Neil Hyslop; Matthew Coomber
Office holder number(s)
9970; 24430
Last date for proving
20 November 2026
Contact
The Joint Liquidators, Tel: 020 7951 6477; Alternative contact: Melanie Hellmuth

What this notice means

A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.

Read more: What is Liquidation?.

All notices for Novartis Europharm Limited

3 Gazette notices on record for company no. 03068306, newest first. The full history, with last filed accounts, is on the Novartis Europharm Limited company record.

  1. Appointment of liquidators (MVL) 08 Oct 2026
  2. Resolution for winding up (MVL) 08 Oct 2026

How does this notice affect you?

Choose what applies and we'll point you at the right next step.

Would rather just talk? 020 7720 8000

Related guidance

Free, practical guides from K2 on what this kind of notice means for directors.

More liquidation notices

← Back to all notices

Frequently asked questions

Is Novartis Europharm Limited in financial difficulty?

No — this is a solvent process. A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress. The London Gazette published a Notices to creditors (MVL) for Novartis Europharm Limited (company no. 03068306) on 08 October 2026.

What does a Notices to creditors (MVL) mean?

A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.

Who is dealing with the liquidation?

The office holders named in the notice: Derek Neil Hyslop; Matthew Coomber, appointed 30 September 2026. Creditors, employees and anyone holding goods or money belonging to the company should contact them directly, quoting the company number.

Source: The London Gazette and Companies House. Contains public sector information licensed under the Open Government Licence v3.0. © Crown copyright. This page is provided by K2 Partners for information only and is not legal or financial advice.